Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bw-755C SCHEMBL30088397 | 1.00 | ALOX5 (1.00) | ALOX5PTGS1PTGS2MAPTGAA | |
| Bw-755C SCHEMBL1040411 | 0.98 | ALOX5 (0.97) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL10830542 | 0.85 | ALOX5 (0.74) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL10954928 | 0.81 | ALOX5 (0.68) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL908075 | 0.80 | ALOX5 (0.66) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL10917829 | 0.78 | MAPT (0.66) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL9813214 | 0.78 | ALOX5 (0.64) | ALOX5PTGS1PTGS2MAPTGAA | |
| Hydrochloric Acid SCHEMBL11114350 | 0.77 | ALOX5 (0.63) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL7721910 | 0.76 | ALOX5 (0.61) | ALOX5PTGS1PTGS2MAPTGAA | |
| SCHEMBL907934 | 0.76 | ABL1 (0.64) | ALOX5PTGS1PTGS2MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238254-A1 | PHARMACOLOGICAL INTERVENTION OF THE ARACHIDONIC ACID PATHWAY TO CURE AMYOTROPHIC LATERAL SCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-18 | — | — | US | claimed |
| WO-2022251254-A1 | PHARMACOLOGICAL INTERVENTION OF THE ARACHIDONIC ACID PATHWAY TO CURE AMYOTROPHIC LATERAL SCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-12-01 | — | — | WO | claimed |
| EP-1572185-A4 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | INSMED INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-7365099-B2 | Reducing lipoxygenase activity by administering enzyme inhibitor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-04-29 | — | — | US | claimed |
| EP-1572185-A1 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | Insmed Incorporated (US) | 2005-09-14 | — | — | EP | claimed |
| US-20040198800-A1 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | INSMED INCORPORATED | 2004-10-07 | — | — | US | claimed |
| US-20040146539-A1 | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits | GUPTA SHYAM K (US) | 2004-07-29 | — | — | US | claimed |
| WO-2004058240-A1 | LIPOXYGENASE INHIBITORS AS HYPOLIPIDEMIC AND ANTI-HYPERTENSIVE AGENTS | INSMED INCORPORATED (US) | 2004-07-15 | — | — | WO | claimed |
| US-20020197301-A1 | Animal body fat control | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-12-26 | — | — | US | claimed |
| US-5652255-A | ADMINISTERING NITROIMIDAZOLE DERIVATIVE NITRIC OXIDE SYNTHASE INHIBITOR; ANTITUMOR AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-07-29 | — | — | US | claimed |
| EP-0022578-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-PYRAZOLINE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-06-29 | — | — | EP | claimed |
| EP-0022578-A1 | Pharmaceutical compositions containing 3-Amino-pyrazoline derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-01-21 | — | — | EP | claimed |
| US-20240238254-A1 | PHARMACOLOGICAL INTERVENTION OF THE ARACHIDONIC ACID PATHWAY TO CURE AMYOTROPHIC LATERAL SCLEROSIS | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| EP-3771709-B1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | FARMINGTON PHARMA DEV (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-0055418-A2 | Pyrazoline derivatives, processes for their preparation and pharmaceutical formulations containing them | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-07-07 | — | — | EP | disclosed |
| EP-0038674-A1 | Medicinal composition for treatment of allergic diseases | Takeda Chemical Industries, Ltd. (JP) | 1981-10-28 | — | — | EP | disclosed |
| EP-0022578-A1 | Pharmaceutical compositions containing 3-Amino-pyrazoline derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-01-21 | — | — | EP | disclosed |
| US-4149005-A | Process for preparing 1-phenyl-3-aminopyrazoles | MONTEDISON S.P.A. (IT) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | ALOX5 1401/4885PTGS1 277/4885PTGS2 448/4885 |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | ALOX5 3657/4885PTGS1 4224/4885PTGS2 4500/4885 |
| US-20040198800-A1 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents | ALOX5, ALOX15, ALOX15B | ALOX5 1/4885PTGS1 14/4885PTGS2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.